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Aims: Bacteremic pneumococcal pneumonia (BPP) is a severe condition. To evaluate
seasonal  distribution, mortality, serotype frequencies, antimicrobial susceptibility, and dif-
ferent severity scores among patients with BPP.
Patients and methods: Patients were identiﬁed by laboratory data and restricted to adulthood.
Standard  methods were used for serotyping and antimicrobial susceptibility. Risk factors
were  analyzed by univariate and multivariate methods. Severity scores (APACHE II, CURB-65
and  CAP PIRO) were compared using ROC curves.
Results: Sixty events of community-acquired BPP occurred between 2005 and 2010. A sea-
sonal pattern was detected. Mean age was 72.1 years old (81.4% ≥60 years). All had a
predisposing  factor. Previous inﬂuenza (3.3%) or pneumococcal immunization (1.7%) was
infrequent.  Admission to critical units was required by 51.7%. Twenty-two serotypes were
identiﬁed  among 59 strains. Only one strain had intermediate resistance to penicillin (1.7%).
In-hospital  mortality reached 33.3%. Multivariate analysis identiﬁed a CAP PIRO score > 3 (OR
29.7; IC95 4.7–187), age ≥65 years (OR 42.1; IC95 2.2–796), and a platelet count < 100,000/L
(OR  10.9; IC95 1.2–96) as signiﬁcant independent factors associated with death. ROC curve
analysis  did not reveal statistical differences between the three severity scores to predict
death  (AUC 0.77–0.90). The prognostic yield for all of them was limited (Positive Likelihood
Ratio:  1.5–3.8).Conclusions: BPP had a hig
ation  to resistant isolates,
related  to death and the p
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Introduction
Invasive infections due to Streptococcus pneumoniae are an
important  cause or morbidity and mortality with a high dis-
ease  burden.1 In addition, invasive disease cases will probably
increase  in the near future due to population aging.2 Bac-
teremic  pneumococcal pneumonia represents an invasive
disease  that is linked to extreme ages and comorbidities.3,4
It has sometimes been associated with a range of differ-
ent  serotypes, antibiotic resistance and a high case-fatality
ratio.3,5–7 Updated information about antibiotic resistance and
serotype  distribution is needed for antimicrobial treatment
and  to evaluate vaccine efﬁcacy. However, data regarding
serotype frequencies is scarce in adults in several countries
of  Latin America because it has mainly been focused on
children.8,9 In addition, different severity scores have been
applied  in patient with community-acquired pneumonia or in
those seriously-ill4,10,11 but not in a speciﬁc group of patients
such as those with bacteremic pneumococcal pneumonia.
We  report the result of a 6-year period retrospective study
in  patients with bacteremic pneumococcal pneumonia. The
aims  were to examine seasonal distribution, patient’ char-
acteristics,  mortality rate, use of intensive care resources,
serotype frequencies, antimicrobial susceptibility, and sever-
ity  scores prediction yield. Risk factors associated to critical
care  unit admission and mortality, were  also explored.
Patients  and  methods
Design  of  study  and  setting
Retrospective and descriptive study performed at the Hospital
Militar  de Santiago, Chile. This institution is a 250-bed gen-
eral  hospital for active or retired military personnel and their
relatives.
Inclusion  criteria  and  variables  included
Every adult patient ≥ 18 years, admitted between 2005 and
2010  with S. pneumoniae growing in blood cultures, and with
respiratory  symptoms and/or pneumonia was  included.
Potential cases were  identiﬁed using the microbiology labora-
tory  database. Medical charts were reviewed and data on the
following  variables were  obtained: co-morbidities (pulmonary
diseases, cardiac disease, renal failure, diabetes mellitus),
immunosuppression, alcoholism or tobacco consumption,
inﬂuenza and pneumococcal vaccination coverage, clini-
cal  manifestations, physical examination, laboratory values,
chest  X-ray and/or CT information, admission to intermediate
or  critical care unit, use of vasoactive drugs or shock, antimi-
crobial  therapy, steroid use during the ﬁrst 72 h of admission,
length  of stay (LOS) and hospital mortality. APACHE II,
CURB-65  and CAP-PIRO severity scores were applied.10,11
Data on antimicrobial susceptibility and serotyping were
included.  The latter was  performed in the national reference
laboratory. The following operative deﬁnitions were  applied:
tobacco  consumption (any quantity of cigarettes per day
in  the last two years), alcohol consumption (any quantity 1 4;1  8(2):115–123
of  ethanol consumption per day), shock (arterial systolic
pressure < 90 mmHg  with no response to ﬂuid resuscitation or
need for vasoactive drugs), acute renal injury (serum creati-
nine  level > 1.5 mg/dL at admission or 50% increase above the
baseline  value), acute respiratory distress syndrome (ARDS:
PaFiO2 < 200 and bilateral inﬁltrates), and complicated pleural
effusion  (purulent pleural ﬂuid or bacteria on gram stain,
requiring a chest tube or surgical drainage).
Statistical  analysis
Clinical information is presented in a descriptive manner.
Continuous variables were  categorized to facilitate anal-
yses.  Potential factors linked to in-hospital mortality or
intermediate-intensive care unit admission, were  explored
using  chi-square or two-sided Fisher’s exact test. Univariate
analysis including odds ratios (OR) was  performed, adding 0.5
to every cell in the 2 × 2 contingency table when null cells
were  present. Multivariate analysis was developed through
binary  logistic regression. ROC curves were applied in order
to  compare different numerical variables associated to higher
in-hospital  mortality, and cutoff values were  established. The
areas  under the curve (AUC) from different predictive scales
were  compared using Epidat software.
Results
General  features
From 2005 to 2010, sixty events of community-acquired bac-
teremic  pneumococcal pneumonia occurred in 59 patients.
One  patient had two events three years apart from each other.
In  this case demographics, tobacco smoking, alcohol con-
sumption  and co-morbidities were counted once, but data
on  clinical manifestations, laboratory, radiologic, and vaccine
coverage,  were  counted separately.
Near two-thirds of patients were  females. Mean age was
72.1  years old (range 20–96; Table 1). Over 80% of the sub-
jects  was 60 years or older, and half was  older than 75 years.
In  addition, one third declared tobacco smoking and almost
20%  were  alcohol consumers but a detailed characterization
on the quantity used was  not possible. Medical morbid con-
ditions  were frequent in this series, heart disease, different
pulmonary conditions, diabetes mellitus, and chronic renal
failure  predominated. All patients had a predisposing con-
dition  and 76% had co-morbidities. No patients with HIV
infection  or solid or bone marrow transplantation were  iden-
tiﬁed  in this series, and inﬂuenza or pneumococcal vaccine
coverage was exceedingly rare (Table 1).
Bacteremic events were characterized by a severe clini-
cal  condition reﬂected in the relative higher frequency of
cyanosis,  respiratory rate > 30 min–1, and hypotension (Table 2,
whole  group column). More than half had an APACHE II
score  > 15 points and two-thirds a CAP PIRO score > 2. Cough,
fever,  and lung sounds in the form of rales or crackles were  fre-
quent  (∼80%, Table 2, whole group). Most patients presented
one  to seven days of symptoms before admission, but near 15%
of events started on the same day of hospitalization (Table 2,
whole  group).
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Table 1 – General features among patients with
community-acquired bacteremic pneumococcal
pneumonia admitted to Hospital Militar de Santiago,
2005–2010.
n (%)
Patients/events 59/60
Female gender 38 (64.4%)
Age > 60 years old 48 (81.4%)
Age > 75 years old 31  (52.5%)
Tobacco smoking 22 (37.3%)
Alcohol consumption (any quantity) 11 (18.6%)
Co-morbidities
Heart disease 28 (47.5%)
COPD – chronic bronchitis 14 (23.7%)
Asthma 1 (1.7%)
Diffuse pulmonary disease 2 (3.4%)
Any pulmonary condition 17 (28.8%)
Diabetes mellitus 15 (25.4%)
Chronic renal failure 12 (20.3%)
Chronic liver disease 5 (8.5%)
Any comorbidity 45 (76.3%)
Age > 60 years old or co-morbidities 59 (100.0%)
b
t
l
wInﬂuenza vaccine 2 (3.3%)
Pneumococcal polysaccharide vaccine 1  (1.7%)
As a group (Table 3, whole group column), patients with
acteremic pneumococcal pneumonia presented tachycardia,
achypnea, fever, leucocytosis, elevated C reactive protein,
ow  serum albumin concentration, and respiratory failure
ith  low PaFiO2 index together with increased values of
Table 2 – Clinical manifestations and severity scores at admissi
Hospital Militar de Santiago, 2005–2010.
Intermediate and
critical  care units
Gen
Preceding upper respiratory symptoms 8/31 (25.8%) 7
Days with symptoms
<1  day 5/31 (16.1%) 3
1–3 days 13/31 (41.9%) 13
4–7 days 11/31 (35.5%) 12
>7 days 2/31 (6.5%) 1
Cough 28/31 (90.3%) 20
Dyspnea 23/31 (74.2%) 15
High fever (T > 38 ◦C) 24/31 (77.4%) 23
Sputum 24/31 (77.4%) 16
Cough + high fever + sputum 20/31 (64.5%) 15
Cyanosis 8/31 (25.8) 6
Hemoptysis 1/31 (3.2% 0
Pulse rate > 100/min 20/31 (64.5%) 10
Respiratory rate ≥ 30/min 24/31 (77.4%) 7
Hypotension 13/31 (41.9%) 6
Shock 11/31 (35.5%) 0
Pulmonary rales or crackles 23/31 (74.2%) 27
Multilobar lung inﬁltrates 18/31 (58.1%) 0
Complicated pleural effusion 4/31 (12.9%) 2
ARDS 25/31 (80.6%) 7
C-reactive protein > 150 mg/L 21/29 (72.4%) 2
CURB-65 score > 2 22/31 (71.0%) 10
APACHE score > 15 24/31 (77.4%) 10
CAP PIRO score > 2 27/31 (87.1%) 144;1 8(2):115–123  117
blood  urea nitrogen and serum creatinine concentration.
Ten percent had complicated pleural effusion and required
a  chest tube or surgical drainage. Thirty percent presented
multilobar lung inﬁltrates and 57% ARDS (Table 2, whole
group).
Microbiological  characterization
Twenty-two serotypes were identiﬁed among 59 strains. One
isolate  was  untypeable and one strain was  not analyzed. Two-
thirds  of the sample were represented by nine predominant
serotypes (14, 7f, 9v, 12f, 22f, 6a, 8, 4, and 1) (Table 4). Other
13  serotypes were  detected once or twice in this period (23a,
23f,  5, 6b, 13, 15f, 17f, 18f, 19a, 3, 9n, poolr, 33f). Most frequent
serotypes were  evenly distributed through the whole period.
The  same serotype was found in both isolates from the patient
with  two bacteremic episodes (serotype 5).
E-test and disk diffusion were used to study antimicrobial
susceptibility (Table 5). MIC50 and MIC90 values for penicillin,
amoxicillin and cefotaxime were remarkably low and only
one  strain with intermediate susceptibility to penicillin was
detected.  No resistant isolates to levoﬂoxacin or vancomycin
were  identiﬁed by the disk diffusion method.
Place  of  hospitalization  and  evolutionThirty-one patients were admitted to an intermediate or crit-
ical  care unit (51.7%). Thirty per cent of bacteremic events
required mechanical ventilation. Antimicrobial therapy was
on of 60 events of bacteremic pneumococcal pneumonia.
eral wards Whole  group Odds Ratio (95%CI) for
signiﬁcant differences
between critical units and
general  wards
/29 (24.1%) 15/60 (25.0%)
/29 (10.3%) 8/60 (13.3%)
/29 (44.8%) 26/60 (43.3%)
/29 (41.4%) 23/60 (38.3%)
/29 (3.4%) 3/60 (5.0%)
/29 (69.0%) 48/60 (80.0%) 4.2 (1.0–17.5) p = 0.05
/28 (53.6%) 38/59 (66.4%)
/28 (82.1%) 47/59 (79.7%)
/29 (55.2%) 40/60 (66.7%)
/29 (51.7%) 35/60 (58.3%)
/29 (20.7%) 14/60 (23.3%)
/28 (0.0%) 1/59 (1.7%)
/29 (34.5%) 30/60 (50.0%) 3.4 (1.2–9.9) p < 0.05
/29 (24.1%) 31/60 (51.75%) 10.7 (3.2–35.6) p < 0.001
/29 (20.7%) 19/60 (31.7%)
/29 (0.0%) 11/60 (18.3%) 33.1 (1.8–593) p < 0.001
/29 (93.1%) 50/60 (83.3%)
/29 (0.0%) 18/60 (30%) 80.8 (4.5–1443) p < 0.001
/29 (6.9%) 6/60 (10.0%)
/25 (28.0%) 32/56 (57.1%) 10.7 (3.1–37.3) p < 0.001
/27 (7.4%) 23/56 (41.1%) 32.8 (6.3–171) p < 0.001
/29 (34.5%) 32/60 (53.3%) 4.6 (1.6–13.8) p = 0.005
/29 (34.5%) 34/60 (56.7%) 6.5 (2.1–20.3) p < 0.01
/29 (48.3%) 41/60 (68.3%) 7.2 (2–25) p < 0.01
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Table 3 – Physical exam parameters, laboratory values and severity scores results among 60 events of bacteremic
pneumococcal pneumonia, Hospital Militar de Santiago, 2005–2010.
Variable Intermediate and
critical care unit mean
(range)
n = 31
General ward mean
(range)
n  = 29
Whole group mean
(range)
n  = 60
Signiﬁcant  differences by
Mann–Whitney test
between  critical units and
wards
Mean arterial pressure
(mmHg)
79.4  (53–147) 84.0 (43–120) 81.6 (43–147)
Diastolic  blood pressure
(mmHg)
61.9  (33–120) 68.3 (30–100) 65.0 (30–120)
Pulse  rate/min 108.6  (60–148) 97.6  (71–123) 103.3  (60–148) <0.05
Respiratory rate/min 32.8 (18–45) 25.4  (18–40) 29.2  (18–45) <0.001
Axilar temperature (◦C) 37.5 (36–39.6) 37.2 (35–39.5) 37.4 (35–39.6)
White  cell count/L 13,544 (1300–33,100) 13,186 (2400–30,900) 13,371 (1300–33,100)
Hematocrit (%) 35.8 (17.0–48.0) 35.5 (21.6–44.8) 35.7 (17.0–48.0)
Platelets/L 188,645 (19,000–396,000) 200,896 (21,000–457,000) 197,950 (19,000–457,000)
C  reactive protein (mg/L) 180.8 (34–306) 98.7 (14.5–197) 141.2 (14.5–306) <0.001
Serum albumin (g/dL) 3.0 (1.0–4.3) 3.2 (1.8–4.5) 3.1 (1.0–4.5)
Serum  sodium
concentration (mEq/L)
136.8  (128–146) 137.1 (124–150) 137 (124–150)
Serum  potassium
concentration (mEq/L)
3.8  (2.6–5.2) 4.1 (3.3–5.6) 4.0 (2.6–5.6) <0.05
Blood urea nitrogen
(mg/dL)
36.1  (11–99) 32.7 (6–138) 34.4 (6–138)
Serum  creatinine level
(mg/dL)
1.5  (0.4–5.5) 1.4 (0.1–9.1) 1.4 (0.1–9.1)
Arterial  pH 7.34  (7.1–7.5) 7.4  (7.2–7.5) 7.37  (7.1–7.5)
Arterial  pCO2 (mmHg) 39.5 (22–76) 34.2 (19.7–55) 37.1 (19.7–76)
Serum  bicarbonate
(mEq/L)
20.9  (10–30) 22.2 (11–30) 21.5 (10–30)
PaFiO2 158.2 (51–268) 233.4 (49–364) 191.8 (49–364) 0.01
CURB-65 score 3.1 (1–5) 2.1 (0–5) 2.6 (0–5) <0.01
CAP PIRO score 4.0 (1–6) 2.6 (1–6) 3.4 (1–6) <0.001
4) 
15) APACHE II score 20.7 (5–41) 12.7 (6–2
Glasgow score 13.9 (5–15) 14.3 (11–
started three to four days after symptoms appeared (range
0–21,  median 3, IQR 1–5 days). All events were adequately
treated from the start according to susceptibility studies. In
addition,  40.7% (n = 24) received corticosteroid therapy during
the  ﬁrst 72 h of hospitalization. The mean accumulated dose
for  this period was  equivalent of 151 mg  of prednisone (range
38–650  mg). In-hospital mortality reached 33.3% (20 out of 60
Table 4 – Serotype distribution among 59 strains of
Streptococcus pneumoniae isolated during bacteremic
events.
Serotype N % Accumulated %
14 7 11.7 11.7
7f 6 10.0 21.7
9v 5 8.3 30.0
12f 4 6.7 36.7
22f 4 6.7 43.3
6a 4 6.7 50.0
8 4 6.7 56.7
4 3 5.0 61.7
1 3 5.0 66.7
Other serotypes 18 30.0 96.7
Non typeable 1 1.7 98.3
Not done 1 1.7 100.0
Total 60 100.016.8 (5–41) <0.001
14.1 (5–15)
bacteremic events). Length of stay ranged from one to 93 days
(mean  13.3 days).
Risk  factors  associated  to  admission  to  intermediate  or
critical  care  unit
Univariate analysis identiﬁed several factors signiﬁcantly
associated with admission to intermediate or critical care
unit.  Categorical variables such as tobacco smoking (OR 3.1;
95%  CI 1.0–9.5, p < 0.05), cough (OR 4.2; 95% CI 1.0–17.5,
p = 0.05), tachycardia (OR 3.4; 95% CI 1.2–9.9, p < 0.05), respi-
ratory  rate > 30 min–1 (OR 10.7; 95% CI 3.2–35.6, p < 0.001),
shock (OR 33.1; 95% CI 1.8–593, p < 0.001), multilobar inﬁl-
trates  (OR 80.8; 95% CI 4.5–1443, p < 0.001), ARDS (OR 10.7;
95%  CI 3.1–37.3, p < 0.001), C-reactive protein > 150 mg/dL (OR
32.8;  95% CI 6.3–171, p < 0.001), APACHE II score > 15 (OR  6.5;
95%  CI 2.1–20.3, p < 0.01), CURB-65 score > 2 (OR 4.6; 95%
CI  1.6–13.8, p = 0.005), and CAP PIRO score > 2 (OR 7.2; 95%
CI  2–25, p < 0.01) (Table 2) were associated to hospitaliza-
tion in critical units. This association was also established
for  the following continuous variables for higher values:
pulse  and respiratory rate, C-reactive protein, APACHE II
score,  CURB-65, CAP PIRO score (Table 3), and for lower
values of PaFiO2 index and serum potassium concentra-
tion (Table 3). Multivariate analysis indicated that only a
C-reactive  value >150 mg/L was  independently associated
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Table 5 – Antimicrobial susceptibility studies.
MIC by E-test
Compound n Mean (range) (g/mL) MIC50 (g/mL) MIC90 (g/mL) Susceptible n (%) Intermediate n (%)
Penicillin 60 0.21 (0.004–4.0) 0.03 0.5 59 (98.3%) 1 (1.7%)
Amoxicillin 42 0.17 (0.004–2.0) 0.03 0.5 42 (100%) 0 (0%)
Cefotaxime 59 0.12 (0.002–1.0) 0.03 0.4 59 (100%) 0 (0%)
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isk  factors  associated  to  in-hospital  mortality
wenty patients died in this series and univariate analysis
dentiﬁed several associations (Table 6). Most relevant fac-
ors  were  CURB-65 score > 2 (OR 39.5; 95% CI 4.7–327.0), CAP
IRO  score > 3 (OR 19.5; 95% CI 4.6–81.0), respiratory rate > 30
OR  18.7; 95% CI 3.7–92.0), Glasgow score < 15 (OR 13.8; 95%
I  3.7–51.7), and age > 65 years (OR 11.4; 95% CI 1.4–94.0).
 LOS > 14 days was  signiﬁcantly associated with reduced
n-hospital mortality (OR 0.1; 95% CI 0.1–0.8). Corticosteroid
herapy was  not linked to any particular effect. Multivari-
te  analysis identiﬁed CAP PIRO score > 3, age ≥ 65 years, and
latelet  count <100,000/L as independent factors linked to
igher  in-hospital mortality (Table 6).
everity  scores  and  in-hospital  mortality
ig. 1 shows receiver operating characteristic curves for in-
ospital  mortality according to PIRO, APACHE II, CURB-65
cores and age. CURB-65 and CAP PIRO scores surpassed the
rea  under the curve (AUC) prediction obtained with APACHE
I  or Age but matched between them (Table 7). Signiﬁcant sta-
istical  differences were found between the AUC of CURB-65
nd  age (p < 0.01); also with CAP PIRO versus age (p < 0.05).
urvival  curves at 30 day since admission using a stratiﬁed
AP  PIRO score (≤3 or >3) was  statistically signiﬁcant (Log
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rank  test p < 0.001) (Fig. 2). Cut-off values optimized with ROC
analysis  and different statistics parameters are displayed in
Table  7. Sensitivity and speciﬁcity regarding prognostic yield
was  limited. Severity scores were  more  useful as negative pre-
dictive  values if the patient was  below the cut-off.
Epidemiological  aspects
Events distribution showed a sporadic pattern along the study
ranging  from 4 to 17 cases per year. There was  a non-
signiﬁcant trend toward case reduction during this period
(Pearson correlation coefﬁcient −0.46; p > 0.05). Over 40% of
cases  were  hospitalized between epidemiological weeks 14
and  26 (Fig. 3).
Discussion
The aims of this study were  to evaluate clinical, epidemio-
logical, and microbiological features, as well as predictors of
mortality  and critical care unit admission in a group of adult
patients  hospitalized for bacteremic pneumococcal pneumo-
nia.  Several ﬁndings deserve attention.
From an epidemiological perspective, a seasonal pattern
was  observed with a higher incidence of cases during mid-fall
and  early winter (weeks 14–26). This phenomenon had been
previously  described in adults, associated to a preceding viral
respiratory  infection and air pollution,12 and peak incidence
of  bacteremic events coinciding with seasonal inﬂuenza
in  Santiago.13 Between 2000 and 2010 a decreasing trend
of  these bacteremic events was observed in parallel to a
CAP PIRO  < 3
CAP PIRO > 3
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1,0
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Fig. 2 – Survival curve until discharge stratiﬁed according to
CAP PIRO score.
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Table 6 – Risk factors associated to in-hospital mortality among 60 events of bacteremic pneumococcal pneumonia.
Hospital Militar de Santiago, 2005–2010.
Factor Odds Ratio IC95 p
Univariate analysis
Admission to intermediate or critical care unit 3.1 1.0–9.9 <0.05
Age ≥ 65 years 11.4 1.4–94.0 <0.01
Cyanosis 3.7 1.1–13.1 0.05
Respiratory rate ≥ 30/min 18.7 3.7–92.0 <0.001
Leukocyte count < 7000/L 4.6 1.3–15.9 <0.05
Blood platelets < 100,000/L 4.8 1.2–19.3 <0.05
Serum creatinine over normal limit 3.1 1.0–9.5 <0.05
Blood urea nitrogen > 23 mg/dL 6.0 1.7–21.2 <0.01
Serum  albumin < 3.5 g/dL 5.9 1.2–29.2 <0.05
PaFiO2 < 150 7.5 2.1–26.2 <0.01
ARDS 7.9 2.0–32 <0.01
CAP PIRO score > 3 19.5 4.6–81.0 <0.001
CURB-65 score > 2 39.5 4.7–327.0 <0.001
Glasgow score < 15 13.8 3.7–51.7 <0.001
APACHE II score > 15 7.7 1.9–30.4 <0.01
Length of stay > 14 days 0.1 0.1–0.8 <0.05
Multivariate analysis
CAP  PIRO score > 3 29.7 4.7–187 <0.001
Age ≥ 65 years 42.1 2.2–796 <0.05
Blood platelets < 100,000/L 10.9 1.2–96 <0.05
Table 7 – Cut-off values and diagnostic parameters for different severity scores and age as predictors of in-hospital
mortality.
Variable AUC (IC95) Cut-off Sensitivity Speciﬁcity PPV NPV LR+ LR−
CURB-65 0.901}*(0.83–0.97) >2 0.95 0.67 0.62 0.96 1.5 0.07
PIRO score 0.868}*(0.77–0.96) >3 0.85 0.77 0.77 0.91 3.8 0.19
APACHE II 0.769 (0.64–0.88) >15 0.85 0.57 0.59 0.88 2.0 0.26
Age 0.691}*(0.57–0.83) ≥65 y 0.95 0.35 0.42 0.93 1.5 0.14
sitive
RB-6PPV, positive predictive value; NPV, negative predictive value; LR+, po
∗ p < 0.05 for age versus CAP PIRO score and p < 0.01 for age versus CU
reduction in mortality due to pneumonia among the Chilean
elderly  patients (Pearson coefﬁcient −0.70, data not shown).14
Death rate due to pneumonia decreased from 324 to 222
per  100,000 inhabitants in this age group, and it is possible
that  the decline observed in our work is somehow mirroring
a  global trend in Chile. This change is probably related to
multiple  factors, like, a steadily increase in inﬂuenza vaccine
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Fig. 3 – Weekly distribution of 60 events of bacter likelihood ratio; LR−, negative likelihood ratio.
5.
doses.  At present, 25% of the Chilean population is being
immunized for inﬂuenza (over 4 million doses). In addition,
since  2009 a national polysaccharide 23-valent pneumococcal
immunization program is applied among elderly people,
albeit  with a reduced coverage of the targeted population
(near 6%). Moreover, during the last decade a signiﬁcant
reduction in air pollution has occurred in the metropolitan
gical week
30 35 40 45 50
emic pneumococcal pneumonia, 2005–2010.
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is  precisely the protection against invasive forms of disease,
34,35b r a z j i n f e c t d i s .
rea,15 and a timely, low cost access to medical attention and
ntimicrobial therapy is guaranteed for all aged patients with
TS  II community acquired pneumonia. These interventions
ould  enhance the decreasing trend of this condition in the
uture.  Infant immunization with pneumococcal conjugated
accines can inﬂuence the frequency of invasive pneumo-
occal  disease in adults through its effect on colonization
nd transmission.16 A national immunization program for
nfants  with a 10-valent conjugated pneumococcal vaccine
as  launched in Chile at the end of 2010, but beyond the
tudy  period and could have not inﬂuenced on this decrease.
Three  quarters of our patients had co-morbidities and
ll  had an older age or chronic diseases. The high preva-
ence of co-morbid conditions is a common feature in adult
atients  affected by pneumococcal pneumonia with or with-
ut  bacteremia, underscoring the importance of host factors
n  disease progression, and at the same time, probably
xplaining why the bacteremic condition has not been clearly
ssociated  with a worst prognosis than cases without this
ondition.4,5,17,18 The death toll observed in our work (33%)
s  in line with host characteristic (30%) and similar to ﬁgures
eported  in one group from Brazil.5 However, it is higher than
revious  reports from Chile (10.9 and 20%).3,4 This could be
elated  to the older age range of our patients.
Most of the patients had a severe underlying clini-
al condition and almost 15% suffered an abrupt onset.
yanosis, a respiratory rate > 30/min, and hypotension were
elatively  frequent. Laboratory parameters included renal
BUN  ∼30 mg/dL) and respiratory failure (PaFiO2 ∼190), leuko-
ytosis  (∼13,000/L), elevated C-reactive protein (∼140 mg/L)
nd  low serum albumin (∼3 g/dL). In addition, multilobar inﬁl-
rates  were  detected in almost one third of the subjects and
0%  required a chest tube or surgery due to pleural effusion.
hese  ﬁndings were  also common in other series.3–5
Several risk factors have been associated to a higher risk
f  death in adult patients with pneumococcal infections.
owever, results vary depending on the type of infec-
ion  (pneumonia, bacteremic or non-bacteremic conditions,
eningitis), group of patients (general, HIV-infected, liver dis-
ase, cancer patients), and comparison groups (inﬂuenza,
atients affected by CAP but without microbiological diag-
osis,  etc.).3–5,17–21 A common ﬁnding is the higher risk
ssociated to older age, co-morbidities and severity of infec-
ion.  Death rate in the bacteremic subgroup has been related
o  male gender, renal failure, acidosis, shock, ICU admission,
echanical ventilation, high APACHE II score, leukopenia,
eukocytosis, cancer, speciﬁc pneumococcal serotypes, inap-
ropriate  initial antimicrobial therapy, and infection with a
on-susceptible strain.3,7,21–24 In our work, in-hospital mor-
ality  was  associated to three independent factors: age ≥65
ears  old, CAP PIRO score > 3, and a platelet count < 100,000/L.
hese  ﬁndings came as no surprise because older age is a rec-
gnized  risk factor, a CAP PIRO score > 3 represents a known
igh  risk group of patients affected by community-acquired
neumonia,10 and thrombocytopenia has been occasion-
lly  described as a risk factor in bacteremic patients.25 All
ogether, they reﬂect severely ill patients with predisposing
onditions.
The  only independent factor associated with intensive or
ntermediate  care unit admission was  C-reactive protein. This4;1 8(2):115–123  121
parameter  shows high values in patients with CAP and bac-
teremia  compared to those without this condition.6 Increased
values  are also seen in subjects with CAP and sepsis6 and in
CAP  caused by Legionella pneumophila, Enterobacteriaceae or S.
pneumoniae, but not in cases associated to viruses or atyp-
ical  agents.6 Despite C-reactive protein not be included in
predictive  scales it could be a good, simple biomarker of sever-
ity  in patients with bacteremic streptococcal pneumonia that
deserve  more  studies. However, it will probably not be of uni-
versally  valid because of the lower values reported in patients
with  severe viral infections, such as those with pandemic
inﬂuenza A H1N1.26
Three severity scores were analyzed in this work but they
did  no differ statistically according to the AUC observed in ROC
analysis. A similar AUC for the PIRO score reported in patients
admitted  to ICU with CAP was  observed in another study (0.86
vs.  0.88) as well as for the APACHE II score (0.77 vs. 0.75).10
Using the same cut-off (>3) for the CAP PIRO score applied in
the  above mentioned reference gave a similar sensitivity and
speciﬁcity  (85% vs. 86% and, 77% vs. 79%). These predictive
scores appear to have suboptimal test properties as witnessed
by  their limited sensitivities and speciﬁcities, and low posi-
tive  predictive values and likelihood ratios. Other reports from
Chile  have obtained even lower AUC in the case of CURB-65
and  other predictive scores.27 These limitations suggest that
these  scores can be an option while managing these patients
once  admitted, and clinicians can prefer to use a predictive
scale  that is easier to calculate. The CURB-65 score is currently
used  in Chile in a national guideline on CAP to discriminate
and select patients for appropriate ambulatory treatment or
admission. In this case, this predictive score is applied on an
ambulatory  basis and not after admission.
Results of one randomized trial and meta-analysis sug-
gest  that corticoids may  be of beneﬁt in severely-ill patients
with  CAP.28,29 We found that during the ﬁrst 72 h almost 40%
of  the patients received corticoid therapy, but no reduction
of  in-hospital mortality was observed. According to a post
hoc  analysis of one randomized trial, the beneﬁt on mortality
appears  to be restricted to a speciﬁc group of patients charac-
terized  by high cytokine and reduced cortisol levels.30
S. pneumoniae serotype frequencies have been scarcely
described among adult patients in Latin America.31,32 This
information is highly necessary to evaluate the preven-
tive  potential of immunization programs, and changes or
emergence  of speciﬁc serotypes, especially after vaccine
introduction.9,33 In a comprehensive surveillance study con-
ducted  between 2000 and 2005 in several Latin America
countries, 5657 pneumococcal strains from adult patients
were  serotyped.31 Eleven of the 13 most frequent serotypes
reported in that study, were detected in our series. This match
is  not surprising since 33.5% of the strains of that surveillance
study  came from Chile. According to our ﬁndings the serotype
coverage  of the 23-valent polysaccharide vaccine and the
13-valent  conjugated vaccine would be 72%, and 50%, respec-
tively.  These ﬁgures are rather disappointing because one of
the  most accepted polyvalent polysaccharide vaccine beneﬁtsbut  is serotype speciﬁc. This limitation is enhanced by
the  low immunization record detected in this work, either for
inﬂuenza, as a predisposing condition, or for S. pneumoniae. A
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national immunization program for the latter was  launched
in  2009 in Chile for the elderly population, but coverage still
remains  low with less than 6% of the targeted population
vaccinated by 2011. Five serotypes have been associated to a
higher risk of death (3, 6A, 6B, 9N, 19F) and three to a lower risk
(1,  7F, 8).23,36,37 Twenty-one isolates in our study matched these
serotypes but we  did not ﬁnd association with an adverse out-
come  (data not shown). Of interest, one patient with liver
cirrhosis  had a recurrent infection with the same serotype
(serotype 5) after three years. Although infrequent, this phe-
nomenon  has been described before.38
Low prevalence of antimicrobial resistance among pneu-
mococcal  isolates from adult patients in Chile has been
a  stable ﬁnding.39 Less than 1% of CSF or non-CSF iso-
lates  have shown resistance to penicillin or third generation
cephalosporins. Consequently, inappropriate initial antibiotic
therapy  did not have a contributory inﬂuence in the outcome
of  our patients, as has been demonstrated in other reports.7
In conclusion, our series of adult patients admitted with
bacteremic pneumococcal pneumonia was  characterized by
an older age and a high prevalence of comorbidities, a severe
clinical  condition, frequent hospitalization in critical care beds
(50%), and mechanical ventilation (30%). Some of them had
an  abrupt onset (13%) and previous immunization against
inﬂuenza or S. pneumoniae was  remarkably rare. Multilo-
bar  inﬁltrates were  rather common (30%) and in-hospital
mortality was  high (33%). Cases were not associated to a
few  predominant serotypes, and no beta-lactam resistance
was  observed. Multivariate analysis identiﬁed C-reactive pro-
tein > 150 mg/L as the only factor associated to critical care
hospitalization. In addition, death risk was  linked to three
independent factors: a severity CAP PIRO score > 3, age ≥ 65
years,  and platelet count < 100,000/L. The predictive yield
of  APACHE II, CURB-65 and CAP PIRO scores was  not statis-
tically  different, but demonstrated suboptimal sensitivities
and  speciﬁcities or positive likelihood ratios. Also, a seasonal
pattern  was  observed, with higher incidence of cases during
mid-fall  and early winter. Finally, a non-signiﬁcant decreasing
trend  of bacteremic pneumococcal pneumonia cases was
observed  through the study years that paralleled a reduction
in  mortality due to pneumonia in elderly patients in Chile.
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